Oryzon Genomics S.A.
A clinical-stage biopharma developing epigenetic therapies for cancer and CNS disorders.
ORY | MC
Overview
Corporate Details
- ISIN(s):
- ES0167733015
- LEI:
- 95980063R15RDF29DK13
- Country:
- Spain
- Address:
- Sant Ferran 74, 08940 Cornellà de Llobregat
- Website:
- https://www.oryzon.com/en
- Sector:
- Manufacturing
Description
Oryzon Genomics is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on epigenetics. The company's primary focus is on creating personalized medicines for patients with cancer and central nervous system (CNS) disorders. Utilizing a proprietary epigenetic platform, Oryzon identifies and validates biomarkers and therapeutic targets to advance its pipeline of potential treatments. The company's therapeutic programs aim to address diseases with significant unmet medical needs by regulating gene expression without altering the underlying genetic sequence.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-01-17 08:34 |
La sociedad comunica la conversión de obligaciones convertibles
|
Spanish | 74.9 KB | ||
| 2022-12-20 16:33 |
La sociedad comunica la conversión de obligaciones convertibles
|
Spanish | 74.0 KB | ||
| 2022-12-12 18:16 |
ORYZON presenta resultados finales del ensayo de Fase IIa ALICE con iadademstat…
|
Spanish | 332.1 KB | ||
| 2022-11-24 18:12 |
La sociedad comunica la conversión de obligaciones convertibles
|
Spanish | 73.8 KB | ||
| 2022-11-09 07:24 |
Autorización de la FDA del IND para iniciar un estudio colaborativo de Fase II …
|
Spanish | 212.0 KB | ||
| 2022-11-02 06:20 |
La Sociedad Remite información sobre los estados financieros del tercer trimest…
|
Spanish | 300.3 KB | ||
| 2022-09-27 00:00 |
Motivo de la notificación: Persona con Responsabilidad de Dirección
|
Spanish | 91.4 KB | ||
| 2022-09-16 07:52 |
ORYZON presenta datos preliminares de seguridad agregados y ciegos del estudio …
|
Spanish | 308.2 KB | ||
| 2022-08-11 00:00 |
Motivo de la notificación: Persona con Responsabilidad de Dirección
|
Spanish | 91.4 KB | ||
| 2022-08-09 00:00 |
Motivo de la notificación: Persona con Responsabilidad de Dirección
|
Spanish | 91.4 KB | ||
| 2022-07-19 08:00 |
ORYZON anuncia acuerdo de investigación y desarrollo enmarcado en la iniciativa…
|
Spanish | 182.2 KB | ||
| 2022-07-18 13:00 |
La Sociedad ha procedido en el día de hoy, mediante el otorgamiento de la corre…
|
Spanish | 75.7 KB | ||
| 2022-07-14 00:00 |
Motivo de la notificación: Persona con Responsabilidad de Dirección
|
Spanish | 91.4 KB | ||
| 2022-07-05 07:23 |
La Sociedad suscribe un contrato de inversión por un importe total de hasta 20 …
|
Spanish | 281.2 KB | ||
| 2022-07-04 12:43 |
Oryzon Genomics, S.A. informa sobre los acuerdos adoptados por la Junta General…
|
Spanish | 256.9 KB |
Automate Your Workflow. Get a real-time feed of all Oryzon Genomics S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oryzon Genomics S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oryzon Genomics S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
